#USA #Orlando #Taiho Oncology #Hematologic Cancers #ASH 2025

Taiho Oncology to Showcase 14 Key Presentations at the ASH Annual Meeting

Taiho Oncology, Inc., a company focused on developing groundbreaking therapeutics for hematologic malignancies and solid tumors, has announced that it will present findings from 14 studies at the upcoming 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, from December 6-9, 2025. Among the presentations, six will be delivered orally, emphasizing novel treatment strategies for various blood cancers.

The highlights of these presentations will include results from pivotal studies examining oral regimens consisting of azacitidine combined with cedazuridine, as well as decitabine combined with cedazuridine, specifically targeting patients suffering from myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). These presentations aim to shed light on treatment outcomes and the evolving treatment landscape in hematology.

Key Presentations and Findings

Among the oral presentations, Taiho will detail findings from the Phase 2 component of the ASTX030-01 trial. This rigorously designed randomized, open-label, crossover study compares an all-oral regimen of azacitidine and cedazuridine against traditional subcutaneous azacitidine, aiming to reveal effective treatment modalities that potentially improve patient quality of life. Another oral presentation will explore the Phase 2 section of the ASTX727-03 trial, which assesses both low-dose and standard-dose oral decitabine combined with cedazuridine, specifically in patients diagnosed with lower-risk MDS.

In addition to the oral presentations, Taiho will also present two online abstract posters detailing real-world treatment patterns and outcomes for adults in the U.S. diagnosed with AML. These research findings will provide essential insights into the therapeutic effectiveness of hypomethylating agents, including their combination with venetoclax, while also assessing the time-related burdens associated with initiating parenteral HMA-based therapies within routine clinical practices.

Moreover, independent investigators will contribute ten additional presentations, four of which will also be delivered orally, featuring data derived from collaborative or investigator-led studies funded by Taiho Oncology. These studies include:

• - A UK multicenter Phase 2 trial comparing ASTX727 with hydroxycarbamide or best supportive care in advanced MDS and myeloproliferative neoplasm (MPN).
• - A Phase 2 study investigating the combined all-oral regimen of ASTX727, venetoclax, and revumenib in newly diagnosed AML patients with specific mutations (NPM1m, KMT2Ar, NUP98r).
• - A Phase 1/2 clinical trial assessing the safety and effectiveness of the combination of oral decitabine/cedazuridine with venetoclax for untreated high-risk MDS and CMML.
• - Safety and efficacy results emerging from a Phase 1/2 trial evaluating an all-oral regimen of ASTX727, venetoclax, and gilteritinib for both relapsed/refractory and newly diagnosed patients with FLT3-mutated AML, high-risk MDS, or MPN.

Commitment to Innovation in Hematology

Dr. Harold Keer, Chief Medical Officer of Taiho Oncology, expressed excitement regarding these presentations, stating, "As the leader of oral HMA development, we're thrilled that our data will be showcased prominently at the ASH Annual Meeting. This highlights our growing understanding of novel oral treatment regimens in hematology. Our goal is to deliver therapies that enhance patient comfort and reduce treatment burdens while actively collaborating with reputable institutions to drive the advancement of cancer care. We eagerly anticipate participating in this vital scientific exchange, which is crucial for progressing the field of hematology."

In conclusion, Taiho Oncology’s participation in the ASH Annual Meeting signifies its commitment to advancing research in hematology. The upcoming presentations promise to provide valuable insights into innovative treatment strategies that could reshape the landscape of care for patients with blood cancers, thereby aiming to enhance treatment experiences and outcomes in this critical area of medicine.